Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04202380
Other study ID # A-PROM
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2020
Est. completion date March 1, 2021

Study information

Verified date April 2024
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The preterm prelabour rupture of membranes is defined as the spontaneous rupture of the fetal membranes before 37 completed weeks. Preterm prelabour rupture of membranes complicates up to 3% of pregnancies and is associated with 30-40% of preterm births. preterm prelabour rupture of membranes can result in significant neonatal morbidity and mortality, primarily from prematurity, sepsis, cord prolapse, and pulmonary hypoplasia. In addition, there are risks associated with chorioamnionitis and placental abruption The diagnosis of spontaneous rupture of the membranes is made by maternal history followed by a sterile speculum examination. If on speculum examination, no amniotic fluid is observed, clinicians should consider performing an insulin-like growth factor-binding protein-1 or placental alpha microglobulin-1 test of vaginal fluid to guide further management. One of the risks associated with preterm prelabour rupture of membranes is ascending infection leading to chorioamnionitis, and subsequent fetal and neonatal infection.


Recruitment information / eligibility

Status Completed
Enrollment 300
Est. completion date March 1, 2021
Est. primary completion date January 1, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: 1. Gestational age is between 28 wks and 37wks 2. Singleton living pregnancy. 3. Confirmed Premature Pre-labor rupture of membranes (PPROM). Exclusion Criteria: 1. previable rupture of membranes (<23+6wks) 2. Multiple gestations 3. Macrolide allergy 4. patient receiving combination macrolide therapy 5. lethal fetal anomalies 6. contraindications to expectant management of PPROM at time of diagnosis e.g. concurrent preterm labor, placental abruption, chorioamnionitis or non-reassuring fetal testing

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Azithromycin
Patients will receive Azithromycin orally 1000 mg
Ampicillin
All patients will receive Ampicillin 2gm IV every 6 hours for 2 days
Azithromycin
Azithromycin 500 mg orally once
Azithromycin
Azithromycin 250 mg orally daily for 4 days

Locations

Country Name City State
Egypt Women Health Hospital - Assiut university Assiut

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Days from diagnosis of preterm pre-labor rupture of membranes to delivery. 14 days